Health Affairs, 26, no. 3 (2007): 678-680 doi: 10.1377/hlthaff.26.3.678 © 2007 by Project HOPE	New Online   McAllen, TX & Beyond: An Expert Roundtable   Geography & Reform   Medicaid or Insurance Exchange?   Siren Song of New GME   Public Plan Option: Pro & Con

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Enzi, M. B. Articles by Kennedy, E. M. Search for Related Content PubMed Articles by Enzi, M. B. Articles by Kennedy, E. M. Related Collections Legal/Regulatory Issues Medicare Pharmaceuticals Physicians Research And Technology Consumer Issues

Perspectives

PERSPECTIVE

Risk Management And Intrusions On Medical Practice: Striking A Balance

All drugs have risks. Scott Gottlieb suggests that the federal government should leave management of those risks to medical professionals. At issue is legislation to strengthen the Food and Drug Administration’s (FDA’s) authority and ability to manage those risks over a drug’s life cycle. The Enhancing Drug Safety and Innovation Act (S. 484) would codify the FDA’s authority to impose restrictions on distribution and use after approval of a drug and require those restrictions to be adapted to new information about the safety of the drug. The legislation strikes a realistic balance between risk management and intrusions on medical practice.

                      What's this?